“Western Australia, Queensland, and Ireland Accelerate BioAsia’s Momentum “

Hyderabad, February 17, 2024: BioAsia, Asia’s premier biotechnology and life sciences forum, is proud to announce the expansion of its global network with the addition of new international partners for the 2024 edition. Earlier, Flanders had joined the event as the international region partner. Joining forces with Flanders, BioAsia welcomes Western Australia, Ireland, and Queensland as esteemed partners, further solidifying its position as a leading platform for innovation and collaboration in the life sciences sector.

Ms. Amber- Jade Sanderson, Hon’ble Minister for Health and Mental Health, Western Australia.

 While announcing Global partners, Mr. D Sridhar Babu, Hon’ble Minister for Industries and IT, Government of Telangana said, “It is a great time for life sciences in India, particularly in Telangana. With these new international partnerships, we are taking Telangana to newer heights focussed on economic growth and job creation. But importantly it is about exchanging knowledge, technology transfer to pace up research and innovation.”

 The inclusion of these prestigious regions as global partners underscores BioAsia’s commitment to fostering international cooperation and driving progress in healthcare and biotechnology. With a shared vision of advancing scientific discovery and improving global health outcomes, BioAsia and its partners are poised to create new opportunities for growth and development in the life sciences industry. Each partner brings unique expertise and resources to the table, contributing to BioAsia’s mission of catalysing innovation and driving progress in the pharmaceutical and healthcare sectors.

 Western Australia, renowned for its cutting-edge research and development initiatives, joins BioAsia with a wealth of knowledge in biotechnology and medical innovation. The delegation will be led by Ms. Amber Jade Sanderson, Hon’ble Minister for Health and Mental Health, Western Australia and comprise of about 40 members representing Industry, Research / Academia and Start-ups.

 “We are thrilled to partner with BioAsia 2024, a premier platform for advancing innovation in the life sciences industry. Western Australia’s commitment to healthcare excellence aligns perfectly with Telangana and BioAsia’s mission, and we look forward to leveraging this partnership to drive impactful collaborations and accelerate breakthrough discoveries. Together, we aim to shape the future of healthcare and improve outcomes for patients around the world.” said Ms. Amber- Jade Sanderson, Hon’ble Minister for Health and Mental Health, Western Australia.

 Ireland, a global powerhouse in pharmaceuticals, biotechnology, and medical devices, brings its rich legacy of innovation and entrepreneurship to the BioAsia platform. Ireland’s life sciences sector has a global reputation for operational and innovational excellence with over several leading industry names including  Novartis, AbbVie, Janssen, Pfizer, Sanofi, Lilly, AstraZeneca, MSD, Bristol Myers Squibb and Takeda, who have significant operations contributing to exports of €116+ billion annually.

 Queensland, recognized as a hub for healthcare innovation and excellence, offers BioAsia valuable insights and resources in the fields of biopharmaceuticals, medical technology, and digital health. As a leader in fostering industry-academia partnerships, Queensland’s involvement will undoubtedly bolster BioAsia’s efforts in driving transformative change and breakthrough discoveries.

 Commenting on the partnership, Mr. Jayesh Ranjan, Principal Secretary of the Industries & Commerce and Information Technology, Govt of Telangana said, “BioAsia got scaled at an unprecedent level with every passing year. This year we have Western Australia, Queensland & Ireland coming together as additional partners this year. This will elevate the pace of research through sharing of resources and information exchange as countries come in collaboration. We look forward to the association.”

 “We are thrilled to welcome Western Australia, Ireland, and Queensland as our newest global partners for BioAsia 2024,” said Shakthi M. Nagappan, CEO of BioAsia. “Their participation at BioAsia enhances the diversity and expertise of our vibrant lifesciences ecosystem, enabling us to better serve the needs of our global community and drive meaningful impact in the field of life sciences.”

 With the theme of – “Data & AI: Redefining Possibilities, to deliberate the possibility of reshaping the future of healthtech delivery paradigm in the country.”, BioAsia 2024 is all set to be held between 26th to 28th February 2024 in Hyderabad. Over the three days, prominent industry leaders, distinguished scientists, researchers, and entrepreneurs will come together to discuss humanizing healthcare and will hold constructive discussions on how cross-sectional ecosystems can be integrated, how disruptive technologies can be best utilized, and how we can drive quality healthcare with accessibility and affordability at the forefront in the near future.

BioAsia 2024 confers the Genome Valley Excellence Award

Hyderabad, 1  February, 2024: The 21st edition of BioAsia – the marquee healthcare and Life Sciences event, organized by the Government of Telangana, has announced that the coveted Genome Valley Excellence Award for the year 2024 will be conferred upon Noble Prize winning Paediatrician and Professor Gregg L. Semenza.

International Advisory Board of BioAsia consisting of personalities of national and international reputation including the likes of Dr. Ajit Shetty (Corporate Vice President Global Operations, Johnson & Johnson USA (retd.) and Chairman Emeritus, Janssen Pharmaceutica, Belgium); Dr. Makarand Jawadekar, (Former Director, Pfizer, US); Dr. Robert Naismith, (Former Chairman, JUJAMA, US), among others have made the final selection of the awardee, in light of his prominent ground-breaking discovery in unveiling the hypoxia-inducible factor 1 (HIF-1 protein), a pivotal discovery controlling gene expression in response to fluctuations in oxygen availability.

Professor L. Semenza is currently the C. Michael Armstrong Professor of Genetic Medicine at Johns Hopkins University School of Medicine, USA. His pioneering work in the field is critical in the treatment of diseases such as cancer, anemia, blinding eye diseases, and cardiovascular disorders.


Professor L.Semenza had discovered how cells can sense and adapt to changing oxygen availability. During the 1990s. he identified a molecular machinery that regulates the activity of genes in response to varying levels of oxygen. The discoveries may lead to new treatments of anemia, cancer, and many other diseases. He received the eminent noble prize in Physiology or Medicine in the year 2019 for the discovery on “how cells sense and adapt to oxygen availability”.

Speaking on the announcement of the 2023 Genome Valley Excellence Award, Mr. D Sridhar Babu, Hon’ble Minister for Industries and IT, Government of Telangana said, “I am thrilled that the award committee has decided to confer the prestigious Genome Valley Excellence Award upon Professor Gregg L. Semenza during the 2024 BioAsia. His groundbreaking discovery in unravelling the scientific mysteries stands as a testament to his unwavering dedication to scientific excellence and innovation. I commend Professor Semenza for his outstanding contributions to the field of molecular biology and extend my best wishes for continued success in his future endeavors. His work serves as an inspiration to aspiring scientists and underscores the transformative power of knowledge in shaping a better tomorrow for humanity. I look forward to welcoming him in Hyderabad and I am sure his visit will energize our scientific community to further Hyderabad’s contribution to biomedical innovation.”

“The Genome Valley Excellence Award has achieved the stature of most eminent awards in the field of life sciences. Year on year distinguished personalities have been presented with this coveted honour. Professor Gregg L. Semenza’s pioneering research has not only deepened our understanding of the intricate mechanisms governing gene expression but also holds immense promise in advancing medical science and improving healthcare outcomes. BioAsia feels honored to host such a renowned personality.” said Mr. Jayesh Ranjan, IAS Principal Secretary (I&C), Government of Telangana.

“The significance of the Genome Valley Excellence Award lies not only in honoring outstanding individuals like Professor Gregg L. Semenza but also in highlighting the collective efforts of the lifesciences community towards advancing scientific knowledge and improving human health. Over the years, the Genome Valley Excellence Award has garnered prominence as a coveted recognition within the lifesciences fraternity and has become synonymous with groundbreaking innovation, cutting-edge research, and transformative impact, inspiring individuals and organizations to strive for excellence in their pursuit of scientific advancement. As we celebrate the remarkable contributions of Professor Semenza and other luminaries honored with the Genome Valley Excellence Award, BioAsia reaffirm its commitment to recognize the efforts of incredible personalities addressing global health challenges and create a better future for humanity.,” said Mr. Shakthi M. Nagappan, CEO, BioAsia and Director of Lifesciences and Pharma, Government of Telangana.

Some of the past Genome Valley Excellence Award winners include Nobel laureates such as Dr. Kurt Wuthrich, Ada Yonath, Harald zur Hausen, Barry Marshall, Martin J Evans, Food Laureates, Lasker Awardees, and eminent leaders like CEO of Novartis Mr. Vas Narasimhan, Richard W. Vague Professor in Immunotherapy and CAR-T cell therapy pioneer, Dr. Carl June, CEO of GAVI Dr. Seth Berkley, among others. Last year, the Genome Valley Excellence award was presented to Dr. Drew Weissman, professor at the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, for his breakthrough pioneering research and development of effective mRNA COVID-19 vaccine that has helped save billions of lives globally. In 2021, it was awarded to Padma Bhushan awardees Dr. Krishna Ella and Mrs. Suchitra Ella of Bharat Biotech International Ltd. for the development and commercialisation of vaccines, including COVID-19 vaccine Covaxin. In 2022, it was awarded to Prof. Robert S. Langer, in light of his pioneering research that has led to the development of the first commercial mRNA vaccines used for variety of infectious diseases.